The Oxford-based medtech company OrganOx has developed a groundbreaking device that is changing the face of liver transplantation, by enabling organs to be stored at normal body temperatures for extended periods of time. OrganOx’s liver perfusion machines were approved by the UK’s National Institute for Health and Care Excellence in January 2019, with the technology hailed as a “game-changer” by industry experts.
In October 2018, BOOST&Co gave OrganOx a growth capital loan of £3m, to scale up and expand internationally. The firm’s metra device has now been used to complete more than 500 transplants in 11 countries, and the company’s revenues have increased by around 100% during the past 12 months.
Read our latest news and insights